DBV Technologies appoints Professors Gideon Lack and Philippe Eigenmann to its Scientific Advisory Board. DBV Technologies increases expertise in peanut allergy diagnosis and treatment
Paris, France – 19 October 2009 – DBV Technologies (DBV), a biopharmaceutical company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergies, announces the expansion of its Scientific Advisory Board with the appointments of leading paediatric allergy and paediatric food allergy specialists Professor Gideon Lack and Associate Professor Philippe Eigenmann.
In joining DBV Technologies’ Scientific Advisory Board, Professors Lack and Eigenmann provide the Company with access to their expertise in paediatric food allergy diagnosis and treatment. These SAB appointments are of strategic importance to DBV Technologies, as the Company works towards the initiation of its first US Phase I clinical trial for peanut allergy.
CNIL number: 1544201 v 0
DBV technologies - siège social
Green Square - Bâtiment D
80/84 rue des Meuniers
Phone: +33 (0)1 55 42 78 78
Fax: +33 (0)1 43 26 10 83
SIRET: 441772522 00013
Executive editor: Pierre-Henri Benhamou
Hosting service: OVH www.ovh.com
Design : l’enchanteur www.lenchanteur.com